Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL R&D credit carryforward

R&D credit carryforward at other companies

Nuvation Bio logo
Nuvation BioNUVB
$23.38M+20.6%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's r&d credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's r&d credit carryforward?
Rigel Pharmaceuticals (RIGL) reported r&d credit carryforward of $63.46M in Q4 2025.
What does r&d credit carryforward mean?
This represents the value of research and development tax credits that the company has earned but has not yet been able to utilize to offset its tax liabilities. These carryforwards serve as a potential future tax shield, which can improve cash flow once the company becomes consistently profitable. It is a key indicator of the company's historical investment in innovation and its potential for future tax savings.